Adherence to medication among adult asthma patients in the Middle East and North Africa: results from the ESMAA study.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
01 2021
Historique:
received: 24 09 2020
revised: 15 11 2020
accepted: 17 11 2020
pubmed: 1 12 2020
medline: 29 10 2021
entrez: 30 11 2020
Statut: ppublish

Résumé

Low levels of adherence to asthma medication is reported in many countries worldwide. Improved knowledge of adherence in the Middle East and North Africa (MENA) is needed to address this major public healthcare burden. Assess the level of adherence in patients attending a routine consultation and the relationship between adherence, patient/disease characteristics, disease control, and quality of life. A large-scale cross-sectional epidemiological study was performed on adults suffering from asthma for at least 1 year and without an acute asthma episode within 4 weeks. Adherence was assessed using the MMAS-4 questionnaire©. Predictive factors of adherence were analyzed with logistic regressions. Overall 7203 eligible patients were included in 577 sites. Mean age was 45.4 years (±14.7), 57.2% were female, mean BMI was 28.5 kg/m2 (±6.0), and 11% were active smokers. Good adherence was observed in 23.6% with a country effect (p < 0.001). Higher age, higher SF-8 Mental component score, and high level of control were associated with good adherence (p < 0.001). Patients treated with a fixed combination (ICS + LABA) have better adherence and patients treated with short-acting beta agonist alone have a lower adherence. Good adherence has been noted in 528 uncontrolled patients suggesting the existence of a subgroup difficult to treat and who have severe asthma. Asthma adherence in the MENA is unsatisfactory with less than one quarter of asthma patients having good adherence. This finding highlights the need to improve access to treatment, ensure better control follow-up and improved education among healthcare providers and patients.

Sections du résumé

BACKGROUND
Low levels of adherence to asthma medication is reported in many countries worldwide. Improved knowledge of adherence in the Middle East and North Africa (MENA) is needed to address this major public healthcare burden.
OBJECTIVE
Assess the level of adherence in patients attending a routine consultation and the relationship between adherence, patient/disease characteristics, disease control, and quality of life.
METHODS
A large-scale cross-sectional epidemiological study was performed on adults suffering from asthma for at least 1 year and without an acute asthma episode within 4 weeks. Adherence was assessed using the MMAS-4 questionnaire©. Predictive factors of adherence were analyzed with logistic regressions.
RESULTS
Overall 7203 eligible patients were included in 577 sites. Mean age was 45.4 years (±14.7), 57.2% were female, mean BMI was 28.5 kg/m2 (±6.0), and 11% were active smokers. Good adherence was observed in 23.6% with a country effect (p < 0.001). Higher age, higher SF-8 Mental component score, and high level of control were associated with good adherence (p < 0.001). Patients treated with a fixed combination (ICS + LABA) have better adherence and patients treated with short-acting beta agonist alone have a lower adherence. Good adherence has been noted in 528 uncontrolled patients suggesting the existence of a subgroup difficult to treat and who have severe asthma.
CONCLUSIONS
Asthma adherence in the MENA is unsatisfactory with less than one quarter of asthma patients having good adherence. This finding highlights the need to improve access to treatment, ensure better control follow-up and improved education among healthcare providers and patients.

Identifiants

pubmed: 33253971
pii: S0954-6111(20)30384-X
doi: 10.1016/j.rmed.2020.106244
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106244

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Mahboub Bassam (M)

University of Sharjah, P. O. Box 27272, Sharjah, United Arab Emirates. Electronic address: bhmbhmahboub@dha.gov.ae.

Naser Behbehani (N)

Department of Medicine, Kuwait University, P.O. Box 24923, Safat, 13110, Kuwait. Electronic address: naser.behehani@ku.edu.kw.

Hisham Farouk (H)

AstraZeneca, Ibn Sina Building, Dubai Healthcare City, PO Box 505070, Dubai, United Arab Emirates.

Mohamed Alsayed (M)

AstraZeneca, Ibn Sina Building, Dubai Healthcare City, PO Box 505070, Dubai, United Arab Emirates.

Francois Montestruc (F)

Clinica Group-eXYSTAT, 4 rue Ernest Renan, 92240, Malakoff, France. Electronic address: francois.montestruc@clinicagroup.com.

Hamdan Al-Jahdali (H)

King Saud University for Health Sciences/McGill University/Sleep Disorders Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia. Electronic address: Jahdalih@gmail.com.

Mohamed Nizam Iqbal (MN)

Rashid Hospital, Dubai, United Arab Emirates. Electronic address: drnizam2000@hotmail.com.

Ashraf Al Zaabi (A)

Zayed Military Hospital, Abu Dhabi, United Arab Emirates. Electronic address: ashrafalzaabi@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH